Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  

The good — Novo Nordisk shares phase 2a trial data for obesity treatment 

The bad — Achilles Therapeutics to discontinue TIL-based therapy 

The ugly — Express Scripts files lawsuit against FTC